Omnio AB, is a biotechnical research and development company located in Umeå, northern Sweden. The major aim for Omnio is to develop pro-inflammatory protein based drug candidates based on the plasma protein plasminogen. Plasminogen occurs naturally in sufficient levels in the circulation of healthy people, and can thus be derived through blood plasma fractionation procedures, such as the Cohn Process or ProMetic’s PPPS^TM process.

Omnio performs pre-clinical research on plasminogen and the plasminogen activator system to find solutions to several diseases such as chronic wounds, periodontitis, and tympanic membrane perforation.